Sugi Predict

Sugi Predict / Compounds / SCHEMBL709155

SCHEMBL709155

SCHEMBL709155

Nc1ncnn2ccc(C(=O)Nc3ccc(NC(=O)Nc4ccccc4F)cc3)c12

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKB Q96GD4 10/20 0.77
▸ AURKA O14965 10/20 0.77
▸ KDR P35968 3/20 0.72
▸ PDPK1 O15530 2/20 0.72
▸ LCK P06239 2/20 0.72
▸ CDK1 P06493 2/20 0.72
▸ PIM1 P11309 2/20 0.72
▸ MARK3 P27448 2/20 0.72
▸ GSK3B P49841 2/20 0.72
▸ BLK P51451 2/20 0.72
▸ RPS6KA3 P51812 2/20 0.72
▸ PRKCD Q05655 2/20 0.72
▸ STK3 Q13188 2/20 0.72
▸ ROCK1 Q13464 2/20 0.72
▸ MARK2 Q7KZI7 2/20 0.72
▸ IRAK4 Q9NWZ3 2/20 0.72
▸ FLT3 P36888 2/20 0.72
▸ IKBKB O14920 1/20 0.72
▸ EGFR P00533 1/20 0.72
▸ NTRK1 P04629 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL709714 0.88 AURKB (0.81) AURKBAURKAKDRPDPK1LCK
SCHEMBL707878 0.88 AURKA (0.72) AURKBAURKAKDRPDPK1LCK
SCHEMBL710637 0.87 AURKB (1.00) AURKBAURKAKDRPDPK1LCK
SCHEMBL710479 0.86 AURKB (0.73) AURKBAURKAKDRPDPK1LCK
SCHEMBL711213 0.86 AURKB (0.71) AURKBAURKAKDRPDPK1LCK
SCHEMBL710323 0.84 AURKB (1.00) AURKBAURKAKDRPDPK1LCK
SCHEMBL711553 0.83 AURKB (0.81) AURKBAURKAKDRPDPK1LCK
SCHEMBL708728 0.83 AURKB (0.80) AURKBAURKAKDRPDPK1LCK
SCHEMBL707285 0.82 AURKB (0.78) AURKBAURKAKDRPDPK1LCK
SCHEMBL709131 0.82 AURKB (0.70) AURKBAURKAKDRPDPK1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124759-B2 Inhibitors of protein kinases ABBOTT LABORATORIES (US) 2012-02-28 — — US claimed
EP-2297151-A1 INHIBITORS OF PROTEIN KINASES Abbott Laboratories (US) 2011-03-23 — — EP claimed
WO-2009136966-A1 INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2009-11-12 — — WO claimed
US-20090131425-A1 INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2009-05-21 — — US claimed
US-8124759-B2 Inhibitors of protein kinases ABBOTT LABORATORIES (US) 2012-02-28 — — US disclosed
EP-2297151-A1 INHIBITORS OF PROTEIN KINASES Abbott Laboratories (US) 2011-03-23 — — EP disclosed
WO-2009136966-A1 INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2009-11-12 — — WO disclosed
US-20090131425-A1 INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2009-05-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131425-A1 INHIBITORS OF PROTEIN KINASES AURKC, AURKB, PLK1 AURKB 2/4885AURKA 4/4885KDR 2634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.